TheraRadar
← Back
Data updated: Jun 28, 2026

GLAUKOS

Pharma
OphthalmologyCardiovascularGastroenterology Execution: Fair

GLAUKOS is a pharmaceutical company focused on Ophthalmology, Cardiovascular, Gastroenterology. Key products include EPIOXA HD/EPIOXA KIT.

2012
Since
5
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
5 Small Molecules

GLAUKOS's Key Drugs

GLAUKOS's core commercial portfolio centers on PHOTREXA VISCOUS IN DEXTRAN 20%/PHOTREXA, EPIOXA HD/EPIOXA KIT, IDOSE TR, spanning Ophthalmology and Cardiovascular — its most strategically important drugs approved in the last 15 years.

PHOTREXA VISCOUS IN DEXTRAN 20%/PHOTREXA
Other

Fever

Approved 2016
EPIOXA HD/EPIOXA KIT
Other

Fever

Approved 2025
IDOSE TR
Ophthalmology

Open-Angle Glaucoma

FP prostanoid receptor Approved 2023
MITOSOL
Ophthalmology

Glaucoma

Approved 2012
PHOTREXA VISCOUS IN DEXTRAN 20%
Ophthalmology

Keratoconus

Approved 2016

GLAUKOS's Recent FDA Approvals

GLAUKOS secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

EPIOXA HD/EPIOXA KIT NDA
2025-10-17
riboflavin 5'-phosphate sodium
Fever

GLAUKOS's Therapeutic Areas

GLAUKOS's approved drugs and pipeline span 3 therapeutic areas, led by Ophthalmology and Cardiovascular, across 0 biologic and 5 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Ophthalmology 62%
2 drugs Phase 3: 5 Phase 2: 5 Phase 1: 11
Cardiovascular 24%
1 drugs Phase 3: 3 Phase 2: 1 Phase 1: 1
Gastroenterology 14%
2 drugs

GLAUKOS's Top Competitors

GLAUKOS's closest competitors by therapeutic-area and drug-target overlap include BAUSCH, Novartis, and Bayer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

BAUSCH specialty
Ophthalmology, Cardiovascular, Gastroenterology
Novartis big-pharma
Cardiovascular, Ophthalmology
Bayer big-pharma
Cardiovascular, Ophthalmology
B BRAUN specialty
Ophthalmology, Cardiovascular
Takeda big-pharma
Gastroenterology, Cardiovascular

GLAUKOS Pipeline Snapshot

GLAUKOS has 26 active clinical programs from ClinicalTrials.gov — 8 Phase 3, 6 Phase 2 and 12 Phase 1.

8
Phase 3
6
Phase 2
12
Phase 1

Phase 3 Readout Calendar Pro

2 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q1 2028
Gen 2 Travoprost Intracameral Implant
Glaucoma
Estimated · fresh NCT07075718
Q2 2028
Gen 2 Travoprost Intracameral Implant
Glaucoma
Estimated · fresh NCT07495852

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • PHOTREXA VISCOUS IN DEXTRAN 20%/PHOTREXA leads revenue
  • • 5 key drugs tracked

Trial Catalysts

  • • Ophthalmology pipeline focus
  • • 2 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 6/11 completed
  • • Speed: 51 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges